Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07196722 · ClinicalTrials.gov registry record · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
A Phase 2 study of Crohn Disease, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,092
- Enrollment target
- 20
- Study locations
NCT07196722 is a Phase 2 study of Crohn Disease that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 1,092 participants, above the 190-participant average among 71 other Crohn Disease trials with a reported enrollment target (475% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT07196722, a Phase 2 study of Crohn Disease, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,092 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Icotrokinra
Study Locations (20)
California
- Clinnova Research - Anaheim
- Alliance Research Institute, LLC - Canoga Park - Canoga Park
- Southern California Research Center - Coronado
- Om Research, LLC 1 - Lancaster
- TLC Clinical Research Inc - Los Angeles
- GastroIntestinal Bioscience - Los Angeles
- Om Research, LLC 2 - Oxnard
- Clinical Applications Laboratories, Inc - San Diego
- Medical Associates Research Group, Inc. - San Diego
Florida
- American Institute of Research - Cutler Bay
- Nature Coast Clinical Research - Inverness
- Green Leaf Clinical Trials - Jacksonville
- Florida Research Center Inc. - Lakewood Rch
- Sanchez Clinical Research, Inc - Miami
- GCP Clinical Research - Tampa
Arizona
- AZ Gastro Care - Chandler
- Mayo Clinic - Scottsdale
Colorado
- Peak Gastroenterology Associates - Colorado Springs
Connecticut
- Nuvance Health Danbury Hospital - Danbury
Georgia
- Children's Center for Digestive Health Care - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,092 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2032-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07196722
The ClinicalTrials.gov registry entry for NCT07196722 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,092 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 190-participant average among 71 other Crohn Disease trials with a reported enrollment target (475% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07196722 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07196722 about?
NCT07196722 is a clinical study titled "A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease". The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
What is the current status of trial NCT07196722?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,092 participants. The study started on 2025-10-03. Estimated completion is 2032-10-06.
What conditions does trial NCT07196722 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT07196722?
The interventions under investigation include: Placebo (DRUG), Icotrokinra (DRUG).
Who is sponsoring clinical trial NCT07196722?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07196722 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Standardized Microbiota Transplant Therapy in Crohn's Disease
RECRUITING · Phase 2
-
Precise Infliximab Exposure and Pharmacodynamic Control
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant for Crohn's Disease
RECRUITING · Phase 2
-
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.